-+ 0.00%
-+ 0.00%
-+ 0.00%

Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56

Benzinga·05/13/2026 18:35:53
Listen to the news
Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform and raises the price target from $50 to $56.